新辅助化疗治疗乳腺癌患者 TYMS、MTHFR、p53 和 MDR1 基因多态性的分布。
Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy.
机构信息
Clinical Science Department, Universidad de Las Palmas de Gran Canaria, C/Dr. Pasteur s/n, CP 35016, Las Palmas de Gran Canaria, Spain.
出版信息
Cancer Epidemiol. 2010 Oct;34(5):634-8. doi: 10.1016/j.canep.2010.06.013. Epub 2010 Jul 17.
PURPOSE
To investigate the role of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms in breast cancer patients treated with 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy.
RESULTS
Observed allelic frequencies were: TSER, (2) 0.54 and (3) 0.46; MTHFR C677T, (C) 0.59 and (T) 0.41; p53 Arg72Pro, (Arg) 0.73 and (Pro) 0.27; MDR1 C3435T, (C) 0.52 and (T) 0.48. MTHFR allele T and p53 allele Pro were strongly associated with toxicity due to chemotherapy (odds ratio, 7.1 (95% confidence interval, 1.4-36.1; p=0.018) and 7.0 (95% confidence interval, 1.2-40.5; p=0.029), respectively).
CONCLUSION
We introduced new data related to the contribution of p53 codon 72 to toxicity due to 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy in patients with breast cancer.
目的
研究 TSER（TYMS）、C677T（MTHFR）、Arg72Pro（p53）和 C3435T（MDR1）基因多态性在接受 5-氟尿嘧啶和环磷酰胺为基础的新辅助化疗的乳腺癌患者中的作用。
结果
观察到的等位基因频率为：TSER，（2）0.54 和（3）0.46；MTHFR C677T，（C）0.59 和（T）0.41；p53 Arg72Pro，（Arg）0.73 和（Pro）0.27；MDR1 C3435T，（C）0.52 和（T）0.48。MTHFR 等位基因 T 和 p53 等位基因 Pro 与化疗毒性密切相关（比值比，7.1（95%置信区间，1.4-36.1；p=0.018）和 7.0（95%置信区间，1.2-40.5；p=0.029））。
结论
我们介绍了与乳腺癌患者接受 5-氟尿嘧啶和环磷酰胺为基础的新辅助化疗所致毒性相关的 p53 密码子 72 贡献的新数据。
Zotero 插件